17 completed, 8 recruiting, 3 unknown, 2 terminated. 11 Phase 2, 8 Phase 3, 7 Phase 1, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Recruiting 5, Terminated 1 |
| Phase 3 | 8 | Completed 4, Recruiting 2, Terminated 2 |
| Phase 1 | 7 | Completed 6, Recruiting 1 |
| Not applicable | 2 | Completed 2 |
Follow molnupiravir: new trials by email Literature Review of molnupiravir trials Research Report on molnupiravir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) Molnupiravir, Placebo - Coronavirus Disease (COVID-19) | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 3082 | 2024-12-02 | 2026-11-06 |
| Assessing Antiviral Treatments in Early Symptomatic RSV Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human | Phase 2 | Recruiting | University of Oxford | 1000 | 2024-07-25 | 2025-07-02 |
| Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) Molnupiravir, Placebo molnupiravir, Placebo oseltamivir - Influenza Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 161 | 2023-08-21 | 2025-08-06 |
| A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009) MK-4482 - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2023-06-28 | 2026-04-16 |
| A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human | Phase 2 | Recruiting | University of Oxford | 3000 | 2023-02-22 | 2026-04-14 |
| A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011) Molnupiravir - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 64 | 2023-01-20 | 2025-07-11 |
| Real World COVID-19 Antiviral Effectiveness Research Oral Antiviral - COVID-19 | Unknown | Clinical Research Centre, Malaysia | 660 | 2022-12-06 | 2023-05-23 | |
| Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Molnupiravir, Placebo, RSV A Memphis 37b - Respiratory Syncytial Virus | Phase 2 | Completed | Merck Sharp & Dohme LLC | 116 | 2022-11-02 | 2025-07-18 |
| A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa Molnupiravir 200 mg - COVID-19 | Phase 2 / Phase 3 | Completed | University of Witwatersrand, South Africa | 59 | 2022-08-12 | 2025-07-01 |
| Effectiveness and Safety of New Oral Antivirals for COVID-19 Nirmatrelvir/ritonavir, Molnupiravir - COVID-19 | Unknown | Universidade do Porto | 211 | 2022-08-01 | 2023-12-18 | |
| Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients. Molnupiravir - COVID-19, SARS-CoV-2 Infection | Unknown | Serap Yavuz | 2600 | 2022-07-07 | 2024-01-25 | |
| A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003) Molnupiravir - Renal Impairment | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2022-06-29 | 2025-01-28 |
| A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) Molnupiravir - Hepatic Impairment | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2022-06-14 | 2025-01-28 |
| Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers Molnupiravir - Viral Infection, COVID-19 | Not applicable | Completed | Valenta Pharm JSC | 37 | 2022-04-22 | 2023-07-27 |
| Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia) GP30341 capsules 200 mg, Standard therapy - Pharmacokinetics, Safety Issues | Not applicable | Completed | Geropharm | 246 | 2022-03-17 | 2024-07-22 |
| Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era Molnupiravir - COVID-19, SARS-CoV-2 | Completed | Charles University, Czech Republic | 1795570 | 2022-01-01 | 2026-09-15 | |
| TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 casirivimab with imdevimab, sotrovimab, molnupiravir - COVID-19 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1178 | 2021-12-14 | 2025-12-16 | |
| Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19 Molnupiravir (Esperavir), Standard of care - COVID-19 | Phase 3 | Completed | Promomed, LLC | 240 | 2021-12-01 | 2022-10-27 |
| COVID-19 International Drug Pregnancy Registry Antiviral Agents, Monoclonal antibody - Covid19 | Recruiting | Pregistry | 2000 | 2021-12-01 | 2025-09-26 |
Showing 20 of 30. Sign in to see all of them.
COVID-19 (20) · Community-Acquired Pneumonia (1) · Coronavirus Infections (1) · Dengue (1) · Influenza, Human (1) · Pneumonia (1) · Renal Insufficiency (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Merck Sharp & Dohme LLC (10) · University of Oxford (4) · Ridgeback Biotherapeutics, LP (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Charles University, Czech Republic (1) · Clinical Research Centre, Malaysia (1) · Geropharm (1) · KU Leuven (1) · Oxford University Clinical Research Unit, Vietnam (1) · Pregistry (1) · Promomed, LLC (1) · Serap Yavuz (1) · Universidade do Porto (1) · University of Liverpool (1) · University of Witwatersrand, South Africa (1)
United States (10) · United Kingdom (8) · Brazil (6) · Russia (6) · South Africa (6) · France (5) · Spain (5) · Thailand (5) · Colombia (4) · Italy (4) · Mexico (4) · Philippines (4) · Ukraine (4) · Argentina (3) · Japan (3)
Ashwin Balagopal, MD (1) · Cheryl Renz, MD (1) · Dmitriy Pushkar, Academician (1) · Ee Vien Low, Ph.D. (1) · Elizaveta Antonova (1) · Francois WD Venter (1) · Jim Bush, MBChB, PhD (1) · Lubov Shpagina, MD (1) · Peter W Horby (1) · Saye Khoo (1) · Sergey Noskov, MD, Pr. (1)
PMID 33273742, PMID 34473343, PMID 39601078, PMID 32678530, PMID 33031652, PMID 33031764, PMID 33394942, PMID 33545096, PMID 33933206, PMID 34000257, PMID 34013969, PMID 34100024, PMID 34159342, PMID 34450619, PMID 34658014, PMID 34672950, PMID 34699618, PMID 34800427, PMID 34914868, PMID 35022711, PMID 35151397, PMID 35271729, PMID 35667065, PMID 35695334, PMID 35713300, PMID 35908569, PMID 35913747, PMID 36272432, PMID 36435798, PMID 36522698, PMID 36648627, PMID 36734509, PMID 36803992, PMID 37017631, PMID 37060915, PMID 37162745, PMID 37410460, PMID 37466374, PMID 37470445, PMID 37489818, PMID 37690669, PMID 37778363, PMID 37865101, PMID 37973784, PMID 37995070, PMID 38225598, PMID 38272046, PMID 38296965, PMID 38319178, PMID 38319179
2023 (1)